Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRYOSTAT-2
ISRCTN14998314Phase 3Completed
- Sponsor
- Queen Mary University of London
- Start
- Jul 2017
- Modality
- Tissue Cells → Other Cell Types → Cell Therapies, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of cryoprecipitate in Major trauma hemorrhage (MTH) (2 arms), sponsored by Queen Mary University of London. Primary endpoint: All-cause mortality at 28 days. Started Jul 2017; status: completed.
02
Drugs
cryoprecipitate
03
Conditions
Major trauma hemorrhage (MTH)
Beyond the preview
Go deeper on ISRCTN14998314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14998314.